Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian M Feldman

Showing results (61-70 of 280) with videos related to

Pageof 28
Sort By:
Journal of Clinical Epidemiology|October 8, 2010
Survival distributions impact the power of randomized placebo-phase design and parallel groups randomized clinical trialsLusine Abrahamyan, Chuan Silvia Li, Joseph Beyene, et al.
The Journal of Rheumatology|February 3, 2011
Predictors of hip disease in the systemic arthritis subtype of juvenile idiopathic arthritisMichelle Batthish, Brian M Feldman, Paul S Babyn, et al.
Arthritis and Rheumatism|February 13, 2003
Use of complementary and alternative medicine by pediatric rheumatology patientsLorrie E M Hagen, Rayfel Schneider, Derek Stephens, et al.
Haematologica|March 2, 2016
Securing reimbursement for patient centered haemophilia care: major collaborative efforts are neededKarin C Berger, Brian M Feldman, Joan Wasserman, et al.
The Journal of Rheumatology|October 7, 2004
Favorable outcome in patients with renal involvement complicating macrophage activation syndrome in systemic onset juvenile rheumatoid arthritisAthimalaipet V Ramanan, Norman D Rosenblum, Brian M Feldman, et al.
The Journal of Rheumatology|December 22, 2006
The Quality of My Life questionnaire: the minimal clinically important difference for pediatric rheumatology patientsGrace W K Gong, Nancy L Young, Helen Dempster, et al.
Arthritis Care & Research|August 27, 2010
Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugsWendy J Ungar, Vania Costa, Rebecca Hancock-Howard, et al.
Rheumatic Diseases Clinics of North America|April 7, 2018
Strategies for Dealing with Missing Accelerometer DataSamantha Stephens, Joseph Beyene, Mark S Tremblay, et al.
Journal of General Internal Medicine|July 18, 2014
Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia ALusine Abrahamyan, Andrew R Willan, Joseph Beyene, et al.
The Journal of Clinical Psychiatry|August 1, 2015
Neurodevelopment of children prenatally exposed to selective reuptake inhibitor antidepressants: Toronto sibling studyIrena Nulman, Gideon Koren, Joanne Rovet, et al.
Pageof 28

Showing results (61-70 of 280) with videos related to

Sort By:
Pageof 28
Journal of Clinical Epidemiology|October 8, 2010
Survival distributions impact the power of randomized placebo-phase design and parallel groups randomized clinical trialsLusine Abrahamyan, Chuan Silvia Li, Joseph Beyene, et al.
The Journal of Rheumatology|February 3, 2011
Predictors of hip disease in the systemic arthritis subtype of juvenile idiopathic arthritisMichelle Batthish, Brian M Feldman, Paul S Babyn, et al.
Arthritis and Rheumatism|February 13, 2003
Use of complementary and alternative medicine by pediatric rheumatology patientsLorrie E M Hagen, Rayfel Schneider, Derek Stephens, et al.
Haematologica|March 2, 2016
Securing reimbursement for patient centered haemophilia care: major collaborative efforts are neededKarin C Berger, Brian M Feldman, Joan Wasserman, et al.
The Journal of Rheumatology|October 7, 2004
Favorable outcome in patients with renal involvement complicating macrophage activation syndrome in systemic onset juvenile rheumatoid arthritisAthimalaipet V Ramanan, Norman D Rosenblum, Brian M Feldman, et al.
The Journal of Rheumatology|December 22, 2006
The Quality of My Life questionnaire: the minimal clinically important difference for pediatric rheumatology patientsGrace W K Gong, Nancy L Young, Helen Dempster, et al.
Arthritis Care & Research|August 27, 2010
Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugsWendy J Ungar, Vania Costa, Rebecca Hancock-Howard, et al.
Rheumatic Diseases Clinics of North America|April 7, 2018
Strategies for Dealing with Missing Accelerometer DataSamantha Stephens, Joseph Beyene, Mark S Tremblay, et al.
Journal of General Internal Medicine|July 18, 2014
Using value-of-information methods when the disease is rare and the treatment is expensive--the example of hemophilia ALusine Abrahamyan, Andrew R Willan, Joseph Beyene, et al.
The Journal of Clinical Psychiatry|August 1, 2015
Neurodevelopment of children prenatally exposed to selective reuptake inhibitor antidepressants: Toronto sibling studyIrena Nulman, Gideon Koren, Joanne Rovet, et al.
Pageof 28